Personalis Neoantigen Discovery Report

Personalis has launched the Neoantigen Discovery Report for the company's ACE ImmunoID service. The report predicts peptides which can be generated from each expressed somatic variant and then characterizes those by predicting MHC Class I and II binding affinities based on the patient's HLA alleles, and to both self and known antigens. It combines best-in-class and proprietary tools to aide in the rapid evaluation and prioritization of samples and peptides based on a client's needs, the company said.